Collaborative Fund Advisors LLC Purchases New Stake in Merck & Co., Inc. $MRK

Collaborative Fund Advisors LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, HoldingsChannel reports. The fund bought 3,965 shares of the company’s stock, valued at approximately $477,000.

Other large investors have also bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at about $26,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Finally, High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Trading Down 0.2%

NYSE MRK opened at $129.34 on Monday. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $130.29. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock’s fifty day moving average price is $117.37 and its 200-day moving average price is $115.47. The stock has a market cap of $319.44 billion, a P/E ratio of 36.43, a P/E/G ratio of 2.76 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 5.19 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is 95.77%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, Scotiabank raised their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.83.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.